|
rs2231142
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
No associations were observed between the BCRP C421A polymorphism and clinicopathologic or epidemiologic factors, including age, gender, tumor grade, stage, cigarette smoking, family history of cancer and body mass index.
|
15906349 |
2005 |
|
rs2231142
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
No associations were observed between the BCRP C421A polymorphism and clinicopathologic or epidemiologic factors, including age, gender, tumor grade, stage, cigarette smoking, family history of cancer and body mass index.
|
15906349 |
2005 |
|
rs2231142
|
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
No associations were observed between the BCRP C421A polymorphism and clinicopathologic or epidemiologic factors, including age, gender, tumor grade, stage, cigarette smoking, family history of cancer and body mass index.
|
15906349 |
2005 |
|
rs2231142
|
|
Renal Cell Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Carriers with the C/C genotype of the BCRP C421A polymorphism are at risk of developing nonpapillary RCC.
|
15906349 |
2005 |
|
rs2231142
|
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Carriers with the C/C genotype of the BCRP C421A polymorphism are at risk of developing nonpapillary RCC.
|
15906349 |
2005 |
|
rs2231142
|
|
Hormone refractory prostate cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The ABCG2 421 C > A (Q141K) polymorphism may be an important predictor of response and survival in HRPC patients treated with docetaxel-based chemotherapy.
|
17062685 |
2006 |
|
rs2231142
|
|
Diarrhea
|
|
0.030 |
GeneticVariation
|
BEFREE |
One variant, a common functional single-nucleotide polymorphism (SNP) in the ABCG2 gene, was associated with diarrhea in 124 patients treated with oral gefitinib 250 mg once daily; seven (44%) of 16 patients heterozygous for ABCG2 421C>A (Q141K) developed diarrhea, versus only 13 (12%) of 108 patients homozygous for the wild-type sequence (P = .0046).
|
17148776 |
2006 |
|
rs2231142
|
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Genetic polymorphisms of glutathione S-transferase (GST) genes including GSTT1 positive/null, GSTM1 positive/null, and GSTP1 A313G, and genes for reduced folate carrier 1 G80A (RFC1 G80A), methylenetetrahydrofolate reductase C677T (MTHFR C677T), and breast cancer resistant protein C421A (BCRP C421A) were determined for 26 patients by the polymerase chain reaction (PCR) method or by direct sequencing.
|
17180579 |
2007 |
|
rs2231142
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Genetic polymorphisms of glutathione S-transferase (GST) genes including GSTT1 positive/null, GSTM1 positive/null, and GSTP1 A313G, and genes for reduced folate carrier 1 G80A (RFC1 G80A), methylenetetrahydrofolate reductase C677T (MTHFR C677T), and breast cancer resistant protein C421A (BCRP C421A) were determined for 26 patients by the polymerase chain reaction (PCR) method or by direct sequencing.
|
17180579 |
2007 |
|
rs2231137
|
|
Diffuse Large B-Cell Lymphoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
These results suggest that the BCRP G34A and C421A polymorphisms are associated with the risk and survival of DLBCL.
|
17494054 |
2007 |
|
rs2231142
|
|
Diffuse Large B-Cell Lymphoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These results suggest that the BCRP G34A and C421A polymorphisms are associated with the risk and survival of DLBCL.
|
17494054 |
2007 |
|
rs2231142
|
|
Neutropenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic-phenotypic correlates showed a non-significant influence of UGT1A1*28 and ABCG2 c.421C>A polymorphisms on the pharmacokinetics of SN-38 (P > 0.05), as well as severity of neutropenia (P > 0.05).
|
17627617 |
2007 |
|
rs2231142
|
|
Leukopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic-phenotypic correlates showed a non-significant influence of UGT1A1*28 and ABCG2 c.421C>A polymorphisms on the pharmacokinetics of SN-38 (P > 0.05), as well as severity of neutropenia (P > 0.05).
|
17627617 |
2007 |
|
rs2231142
|
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.
|
18243305 |
2008 |
|
rs2231137
|
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.
|
18243305 |
2008 |
|
rs2231142
|
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Increased exposure to PhIP may decrease survival, but the ABCG2 C421A polymorphism does not appear to increase the risk of prostate cancer.
|
18710444 |
2008 |
|
rs2231142
|
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
Increased exposure to PhIP may decrease survival, but the ABCG2 C421A polymorphism does not appear to increase the risk of prostate cancer.
|
18710444 |
2008 |
|
rs2231142
|
|
androgen independent prostate cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Due to the expression of ABCG2 in the prostate, together with the purported role of dietary carcinogens and steroids in the development and progression of prostate cancer, 311 individuals were genotyped for the ABCG2 C421A SNP, 170 patients with androgen-independent prostate cancer (AIPC) and 141 'healthy' controls.
|
18710444 |
2008 |
|
rs2622621
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that heterozygous carriers of the minor alleles of SNPs rs2622621 and rs1481012 had a decreased risk of CRC, respectively, with odds ratios of 0.73 (95% confidence interval 0.56-0.94; P(value)=0.017), and 0.72 (95% CI 0.53-0.97; P(value)=0.03).
|
18775442 |
2008 |
|
rs1481012
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that heterozygous carriers of the minor alleles of SNPs rs2622621 and rs1481012 had a decreased risk of CRC, respectively, with odds ratios of 0.73 (95% confidence interval 0.56-0.94; P(value)=0.017), and 0.72 (95% CI 0.53-0.97; P(value)=0.03).
|
18775442 |
2008 |
|
rs2231142
|
|
Crohn Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Allele frequencies of the cyclooxygenase 2 (COX-2/PTGS2/PGHS2) G-765C and breast cancer resistance protein (BCRP/ABCG2) C421A as well as allele and haplotype frequencies of multidrug resistance 1 (MDR1, ABCB1) SNPs G2677T/A, C3435T and G-rs3789243-A (intron 3) were assessed in a Danish case-control study comprising 373 CD and 541 UC patients and 796 healthy controls.
|
18819034 |
2009 |
|
rs2231137
|
|
Ischemic stroke
|
|
0.020 |
GeneticVariation
|
BEFREE |
The Val12Met SNP in ABCG2 (encoding a transporter of sterols and xenobiotics) was associated with incident ischemic stroke in white and black participants of CHS.
|
19023099 |
2009 |
|
rs2231137
|
|
Cerebrovascular accident
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Val12Met SNP in ABCG2 was associated with stroke in both white (hazard ratio, 1.46; 90% CI, 1.05 to 2.03) and black (hazard ratio, 3.59; 90% CI, 1.11 to 11.6) participants of CHS.
|
19023099 |
2009 |
|
rs2231142
|
|
Diarrhea
|
|
0.030 |
GeneticVariation
|
BEFREE |
This study demonstrates that the ABCG2 Q141K </span>polymorphism may correlate with chemotherapy-induced di</span>arrhea in patients with DLBCL who have received frontline R-CHOP chemotherapy, and this has implications for optimizing treatment with such agents.
|
19032367 |
2008 |
|
rs2231137
|
|
Diffuse Large B-Cell Lymphoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
No differences were observed according to ABCG2 Q141K and V12M genotype in patient characteristics, disease characteristics, response, survival, or hematology toxicity profiles in patients with DLBCL who received frontline R-CHOP chemotherapy.
|
19032367 |
2008 |